CTLA4 and clear cell renal carcinoma: Three public ICB cancer therapy datasets (anti‐PD‐1, anti‐PD‐L1, or anti‐CTLA‐4), including pan‐cancer [50], non‐small cell lung cancer [51], and clear cell renal cell carcinoma [52], were collected from the cBioPortal website (http://www.cbioportal.org/).